Publication | Closed Access

Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial

Surgical OncologyGastrointestinal OncologyGastro-oesophageal Junction AdenocarcinomaMedicinePerioperative TrastuzumabGastroenterologySurgeryHer2-positive Resectable GastricCancer TreatmentOncologyRadiation OncologyCancer Research